Daré Bioscience Reports Q3 2026 Financial Results
Daré Bioscience reported Q3 2026 revenue of approximately $48,000 compared to approximately $2,300 in Q3 2025, with the increase attributable to research and development services revenue under Gates Foundation agreements and initial Flora Sync LF5 sales that began in July 2026. Net loss improved to approximately $3.2 million from approximately $3.6 million in the prior year period, while EPS improved to $(0.18) from $(0.28). The company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q4...
Read source-backed brief